About GrandOmics
GrandOmics is a company based in Haidian (China) founded in 2011. It operates as a Professional Services, Data-as-a-Service, and HealthTech. GrandOmics has raised $29.6 million across 2 funding rounds from investors including Marathon Venture Partners, Matrix Partners China and Zero2IPO Ventures. GrandOmics offers products and services including BAC-long Ultra-Long Sequencing Kit, T2T Pan-Genome Breeding, Third-Generation Metagenomics, Single-Cell Full-Length Transcriptomics, and GrandBox Integrated Solution. GrandOmics operates in a competitive market with competitors including Depixus, Genomics, Seven Bridges Genomics, Hexagon Bio and BC Platforms, among others.
- Headquarter Haidian, China
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Beijing Grandomics Biotechnology Co., Ltd.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$29.6 M (USD)
in 2 rounds
-
Latest Funding Round
$15.1 M (USD), Series B
Jul 02, 2018
-
Investors
Marathon Venture Partners
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GrandOmics
GrandOmics offers a comprehensive portfolio of products and services, including BAC-long Ultra-Long Sequencing Kit, T2T Pan-Genome Breeding, Third-Generation Metagenomics, Single-Cell Full-Length Transcriptomics, and GrandBox Integrated Solution.
Ultra-long sequencing fragments are produced for genomic analysis.
Complete genomes are analyzed for accelerated breeding applications.
Diversity classification is enhanced through new species discovery.
Isoform differences are studied in single-cell transcriptomic research.
Long-read sequencing data is analyzed with high-performance servers.
Funding Insights of GrandOmics
GrandOmics has successfully raised a total of $29.6M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $15.1 million completed in July 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GrandOmics
GrandOmics has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Marathon Venture Partners, Matrix Partners China and Zero2IPO Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Multiple sectors are invested in by this venture capital firm.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for GrandOmics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GrandOmics
Investment portfolio details for GrandOmics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GrandOmics
Detailed financials for GrandOmics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Grandomics Comparisons
Peer comparison for GrandOmics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GrandOmics
GrandOmics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Depixus, Genomics, Seven Bridges Genomics, Hexagon Bio and BC Platforms, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Single-molecule genetic and epigenetic sequencing solutions are provided.
|
|
| Locked | Locked | Locked |
Genomic risk assessment and prevention platform is provided.
|
|
| Locked | Locked | Locked |
Cloud-based platform to analyze, store, and act on genomic data.
|
|
| Locked | Locked | Locked |
Bioinformatics tools are provided for analyzing microbial genomic sequencing data.
|
|
| Locked | Locked | Locked |
Platforms for genomic data analysis and management are provided.
|
|
| Locked | Locked | Locked |
Gene-editing platform and anti-aging therapy for dogs are developed.
|
Detailed competitors of GrandOmics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Grandomics
Complete news archive for GrandOmics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GrandOmics
GrandOmics was founded in 2011 and raised its 1st funding round 5 years after it was founded.
GrandOmics is headquartered in Haidian, China. It is registered at Haidian, Beijing, China.
Depeng Wang is the current CEO of GrandOmics.
GrandOmics is a funded company, having raised a total of $29.6M across 2 funding rounds to date.
GrandOmics is established as a leader in third-generation sequencing technology, focusing on technical development and application expansion. Services are provided across four main modules: scientific services, medical diagnostics, bioinformatics, and advanced manufacturing. Operations are supported by facilities in Beijing and Wuhan, spanning over 5,000 square meters. Advanced platforms like ONT PromethION 48 and PacBio Sequel II are utilized for cutting-edge research. Solutions are offered for genomics, transcriptomics, and microbiomics, catering to both research and medical sectors. Innovation is driven through proprietary software and databases for sequencing analysis. Recognition is received through awards and consistent rankings in the Nature Index.
GrandOmics's top competitors include Novogene Corporation, Depixus and Ingenuity Systems.
GrandOmics offers BAC-long Ultra-Long Sequencing Kit, T2T Pan-Genome Breeding, Third-Generation Metagenomics, Single-Cell Full-Length Transcriptomics, and GrandBox Integrated Solution.
GrandOmics has 4 investors. Key investors include Marathon Venture Partners, Matrix Partners China, Zero2IPO Ventures, and SAIF Partners China.